Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 610

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 610
---
729 |     |       | — |     |        | — |     |        | 451,733 |     |                | 160,000 |     |              | — |     |              |  18,942 |     |           |   993,404 |
| Keith A. Baker                                                     |     |      | 2024 |     |        | 350,000 |     |       | — |     |        | — |     |        |  19,087 |     |                | 140,000 |     |              | — |     |              |  14,363 |     |           |   523,450 |
| Chief Financial Officer                                            |     |      | 2023 |     |        | 332,692 |     |       | — |     |        | — |     |        | 327,946 |     |                | 140,000 |     |              | — |     |              |  13,054 |     |           |   813,692 |

| (1) | The amounts reported represent the aggregate grant date fair value of RSUs granted to the named executive                                                                                                                        
 officers during the 2024 and 2023 fiscal years, calculated in accordance with Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”), Topic 718. Such grant date fair value does not take into 
 account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in Note 2 to Kineta’s financial statements                                  |

406

| included in Kineta’s 2024 Annual Report on Form 10-K. The amounts reported in this column reflect the accounting cost for the RSUs and does not       
 correspond to the actual economic value that may be received upon settlement of the RSUs or any sale of any of the underlying shares of common stock. |

| (2) | The amounts reported represent the aggregate grant date fair value of stock options awarded to the named                                                                                                                                             
 executive officers during the 2024 and 2023 fiscal years, calculated in accordance with FASB ASC Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair 
 value of the awards reported in this column are set forth in Note 2 to Kineta’s financial statements included in Kineta’s 2024 Annual Report on Form 10-K. The amounts reported in